Theseus Pharmaceuticals, Inc. (THRX) Income Annual - Discounting Cash Flows
THRX
Theseus Pharmaceuticals, Inc.
THRX (NASDAQ)
Period Ending: LTM
(Last Twelve Months)
2022
12-31
2021
12-31
2020
12-31
2019
12-31
Report Filing 2023-11-17 2023-03-09 2022-03-10 2020-12-31 2019-12-31
Revenue 0 0 0 0 0
Cost of Revenue 0.488 0.438 0.002 0.002 0.002
Gross Profit -0.488 -0.438 -0.002 -0.002 -0.002
Operating Expenses 66.04 53.65 27.33 6.83 4.94
Research & Development 47.22 35.7 18.33 5.96 4.12
Selling, General and Administrative 19.3 18.39 9.01 0.878 0.818
Other Operating Expenses -0.488 -0.438 -0.002 -0.002 -0.002
Operating Income -66.52 -54.09 -27.34 -6.84 -4.94
Net Non-Operating Interest 5.73 0 0 0 0
Interest Income 7.44 0 0 0 0
Interest Expense 1.72 0 0 0 0
Equity & Other Income/(Expense) 4.18 3.48 0.028 -5.16 -2.24
Income Before Tax -56.61 -50.61 -27.31 -12 -7.18
Income Tax Expense -0.775 -3.53 0 0 0
Income Attributable to Non-Controlling Interest 0.022 0 0 0 0
Net Income -55.86 -47.08 -27.31 -12 -7.18
Depreciation and Amortization 0.083 0.05 0.002 0.002 0.002
EBITDA -66.44 -54.04 -27.33 -6.83 -4.94
Earnings Per Share (EPS) -1.34 -1.22 -0.76 -0.47 -0.28
Diluted Earnings Per Share -1.34 -1.22 -0.76 -0.47 -0.28
Weighted Average Shares Outstanding 43.8 38.49 35.87 25.37 25.37
Diluted Weighted Average Shares Outstanding 43.8 38.49 35.87 25.37 25.37
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us